Cheech And Chong Get Into A Car Accident

Cheech And Chong Get Into A Car Accident

Article by Christopher Macaulay

“Do my insurance benefits cover my medical marijuana costs?”

It’s a question that claimants are increasingly asking of their first-party healthcare insurers, and one that is not always easily answered.

On one hand, the use of cannabis as a legitimate treatment option has grown exponentially in recent years. On the other, the associated medical literature is in somewhat of a nascent stage, and it is not always clear whether marijuana will aid an injured party with their recovery (at least in any clinically verifiable sense).

In the recent LAT case of F.F. and Aviva Insurance Canada,1 the Tribunal was faced with the question of whether a treatment plan for medical marijuana was reasonable or necessary to treat a claimant’s anxiety and depression.


The insurer denied the treatment plan on the basis of a psychiatric expert report. The psychiatrist did not recommend cannabis as a form of treatment for the claimant’s psychological impairments. He highlighted the fact that there was limited clinical research to support the use of marijuana in treatment of anxiety symptoms.

Despite referencing the psychiatrist’s view of the clinical research, the Tribunal did not delve into what this research actually says. It is unclear whether any medical literature was put before the hearing Adjudicator.

The claimant relied predominantly on the opinion of his family doctor for his evidence. The family doctor’s records confirmed that the claimant had reported little relief from traditional psychiatric medication and psychotherapy. However, he had shown a marked improvement in both his psychological and physical well-being with the use of medical marijuana. He had also noticed an improvement in his sleep quality while using the drug.

In light of these results, the claimant’s family doctor was supportive of medical marijuana as a viable treatment option. This opinion was corroborated by a letter from a treating nurse who had also noticed the claimant’s improvements when he began to use marijuana.


The Tribunal preferred the claimant’s evidence and ordered the treatment plan payable in its entirety. The Decision highlighted the fact that the insurer’s expert psychiatric report failed to consider relevant details about the claimant’s treatment course; for instance, that the claimant had already tried traditional psychiatric medication and psychotherapy with little to no improvement before submitting his treatment plan for medical marijuana.

Interestingly, the Decision also ordered the insurer to fund a related treatment plan for a medical marijuana assessment. The Tribunal held that such an assessment would be reasonable “to determine what would be an appropriate marijuana product” for the claimant.

Questions Raised

The Decision was undoubtedly a resounding win for the involved claimant. However, the Tribunal’s underlying reasoning raises the question of whether a claimant who turns straight to medical marijuana, without first attempting more traditional pharmacological interventions, would have the same level of success.

On a separate note, if the Decision’s findings with respect to the marijuana assessment are left to stand, this seems to open the door for cannabis clinics to submit similar assessment costs for nearly every claimant with a medical marijuana prescription. Will a cottage industry of quasi-medical “personalized cannabis evaluations” spring up? Time will tell.

Lessons Learned

One clear takeaway from the Decision is that a blanket reliance on (a lack of) medical literature will not suffice as a primary reason to deny a medical marijuana treatment plan. The Decision implicitly follows the standard set by prior SABS case law that there is no requirement for a claimant to prove to a medical certainty that a treatment will be therapeutic.2

In a broader sense, the Decision presents another example of the ever-increasing role that the cannabis industry is beginning to play within personal injury litigation. In years past, both FSCO and the LAT grappled with the idea of marijuana as a treatment modality by contrasting the illegality of recreational cannabis with its purely clinical uses.3 This distinction has since been blurred through federal legalization of the drug for recreational use. Both first and third party insurers can expect to see an increase in claims factoring medical marijuana into treatment and future care costs as a result.

  1. 18-002994/AABS.
  2. Pacquette and Certas Direct Insurance Company, FSCO A05-000934.
  3. See: Biro v. Unica Insurance Inc., FSCO A109-001753; M.J. and Pembridge Insurance Company, 16-000583/AABS.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Source: Mondaq

Cannabis-infused foods, beverages set to become legal as of December

Read more

Who decides if medical cannabis is a treatment option for you?

Report Shows Canadians Would Take Prescribed Drugs Containing Cannabis

The recent legalization of cannabis usage has had its fair share of discussion lately, and most of it seems to be relatively positive.

by Damian Ali | inhalton

This trend is reflected in the latest Ipsos study, where research has found that two in three (65 per cent) Canadians would be willing to take a drug containing cannabis that their doctor prescribed, if approved by Health Canada and covered by either public or private insurance.

In particular, those more likely to be willing to take these drugs include men (69 per cent), those aged 18-34 (72 per cent), and residents of Ontario (71 per cent).

However, if these drugs were not covered by public or private insurance and patients had to pay out of pocket, about four in ten (39 per. cent) would still be willing to do so.

An overwhelming majority (82 per cent) of Canadians agree that cannabis can relieve pain and other symptoms and that creating medicines based on cannabis could open the door to many new forms of treatment.

Furthermore, over two-thirds (68 per cent) of Canadians are willing to take cannabis to help manage things like chronic pain or depression, potentially interesting for those who suffer from conditions that could be treated with cannabis-based medicines.

For prescription purposes itself, however, 45 per cent of Canadians say their doctor prescribed cannabis willingly, compared to nine per cent of those who were refused by their doctors when asked to prescribe cannabis for whatever reason (i.e. doctor didn’t believe in cannabis’ effectiveness).

The survey was given to a random sample of 2,002 Canadians, aged 18 and over. The poll is accurate to within 2.5 percentage points, 19 times out of 20.

What do you think of cannabis’ effectiveness in prescribed drugs?

Canada’s first medical pot coverage plan and savings calculator launched, the first fully integrated Health and Wellness Marketplace in Canada, has introduced BuyWell Care. The new program is the country’s first guaranteed issue Medical Cannabis Coverage Plan and Medical Cannabis Savings Calculator.

By inputting the form of cannabis and dosage the calculator recommended to them into the BuyWell Care calculator, patients can determine how much they can save on their medical cannabis while purchasing coverage plans through the online application process. The coverage included in the program includes treatments that use cannabis oils, dried flowers, and gel capsules.

“BuyWell Care’s inclusion of coverage for medical cannabis is a true example of the paradigm shift that’s sweeping through the medical landscape,” said Dr. Ira Price, MD, FRCPC, and medical director of Synergy Health Services. “It’s a breath of fresh air.”

Research and findings from Synergy Health Services suggest that BuyWell Care Consumers may realize savings of up to $5,700 per year on their medical cannabis, depending on their province of residence.

“For hard-working Canadians who rely on medical cannabis as part of their treatment regimen, BuyWell Care’s Medical Cannabis Coverage Plan provides a revolutionary way to save money on their expensive medication,” said Amanda LeBlanc, co-founder of

Buyers in Ontario can immediately avail of coverage; for those in other provinces, coverages will be available beginning in Q1 of 2019.

Source: Life | Health Professional

Cannvas Continues Trajectory To Become Household Name in Cannabis Education

Cannvas MedTech Inc. (“Cannvas” or the “Company”) (CSE MTEC) (Frankfurt : 3CM)  (OTCPK : CANVF), a leading digital cannabis educator and business technology company, is pleased to report the steady growth of its products and services line entering 2019 as it persists in assembling a wide-ranging partner network to promote cannabis education, drive audiences to its Cannvas.Me platform and create revenue-generating opportunities.

“We are continuing to amass a strong network of strategic partners across the cannabis and health sciences space to bolster Cannvas.Me content and user databases, contribute to Cannvas Data analytics and reinforce the brand’s mission within the sector,” said Shawn Moniz, Chief Executive Officer, Cannvas MedTech Inc. “We expect to leverage the relationships we’ve nurtured throughout the industry to drive revenue to all aspects of the business, from education and data analysis to creative work and content creation, and feel the Company will continue to make strides through 2019.”

Working toward its goal of becoming the household name for cannabis education, Cannvas has accomplished a great deal going into the new year, solidifying its reputation through the successful launch of the product and services side of the business, generating shareholder value and propelling company growth.

Cannvas executives are actively engaged in talks with leading cannabis companies across a range of sectors for inclusion in the Company’s 2019 media plan. Its partner network will have the opportunity to access ad space allocated across several platforms and user touchpoints to reach thousands of potential customers through geo-targeted promotions while also benefiting from Cannvas Data analytics surveying the industry landscape and returning relevant results and learnings. Cannvas also plans to work with industry leaders to publish and share insights gleaned from its Cannvas.Me platform about how Canadians are learning about cannabis and what areas of interest they have, to help shape public policy and drive corporate decision-making.

Partnership agreements with clinics, pharmacies, insurance agencies and other such organizations promises to generate steady additional income with the potential for ancillary services such as creative work and content creation to strengthen those streams. Physical locations of Cannvas Marché and Cannvas Kiosks offer more potential for revenue generation and new partnerships.

Cannvas partnered with a number of high-profile cannabis-related companies in 2018, operating in wide range of areas within the cannabis industry, including: Namaste Technologies Inc., AgraFlora Organics International Inc. (formerly PUF Ventures Inc.), The Wellness Soldier, MOOD, Business of Cannabis, and the Global Cannabis Partnership.

Cannvas has also benefited enormously from the support of Tech West Canada and expects to continue leveraging the access to markets and international technology events Tech West provides. Tech West Canada has built a proven record of enabling tech companies from Western Canada to effectively deploy international events as prime sales and business development vehicles.

“We have enjoyed early dividends due to our partnerships with leading companies like Namaste Technologies and organizations like Tech West,” said Steve Loutskou, Chief Operating Officer, Global Markets, Cannvas MedTech Inc. “As the leading cannabis technology company in Canada, Namaste brought instant credibility to Cannvas.Me, further to driving future revenue. Tech West has been instrumental by supporting our efforts on the international stage at a number of prestigious conferences – The relationships developed at those conferences lead to important partnerships and we will continue to pursue partnerships with leading cannabis companies in Canada and around the world as we grow our offering to include other languages in support of our recently-announced international expansion program.”

Cannvas announced letters of intent in 2018 with Loop Media Group –, CanvasRX, Natures Hemp, Marihuana Patient Relief, Advica Health and Blox Labs Inc. As part of its growing corporate social responsibility program, Cannvas has also entered into agreements with charitable organizations Pancreatic Cancer Canada and Sistema Toronto, with an eye on expanding that program in 2019.

Cannvas forms strategic partnerships with leading companies to disseminate its cannabis education in a number of ways, benefiting both parties. Cannvas offers a revenue-sharing model to drive users to Namaste’s services should they so choose; AgraFlora Organics and MOODTM will be part of the Cannvas Marché program promoting their own brands and products in locations across Canada; and The Wellness Soldier contributes to Cannvas Culinary content with expert advice and reliable recipes using cannabis to prepare healthy meals.

Cannvas will also be adding two additional independent oversight boards in 2019 to further strengthen its content and connect its brand to outside industries. Users can look forward to the creation of a Science and Wellness Advisory Board and a Culinary Advisory Board with leading experts from Canada and the United States on each board.

Cannvas.Me is an unbiased educational resource for medicinal and adult-use cannabis users offering innovative tools and physician-backed content to audiences wishing to learn about health care through cannabis.

  • Cannvas Academy – educational learning modules created by licensed medical practitioners and certified educators with a focus on health care, lifestyle and wellness;
  • Cannvas Strain Matcher – an interactive experience where users learn which strain is best for alleviating specific ailments;
  • Cannvas Culinary – a culinary training module with recipes, ideas and more;
  • Cannvas Health & Fitness – combining a cannabis-healthy lifestyle with training and fitness activities;
  • Cannvas Cannabis & Science – for active and potential cannabis users interested in learning more about the science of the plant and how it impacts the human endocannabinoid system.

Additional relevant modules and tools will be added to the platform as they become available.The team at Cannvas is always working on new and exciting modules and tools which are added to the platform as they become available. New versions are first introduced in English and then a short time later will come out in German on its sister sites.

About Cannvas MedTech Inc.
Cannvas MedTech is a leading digital cannabis education and business technology company within the health sciences space. We design and build patient-centric platforms that enable our partners to harness the power of data to truly understand their customers.

For additional information:

SOURCE Cannvas MedTech Inc. 

Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates from ILSTV

You have Successfully Subscribed!

Pin It on Pinterest